GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Accounts Payable

Sunho Biologics (HKSE:02898) Accounts Payable : HK$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Accounts Payable?

Sunho Biologics's Accounts Payable for the quarter that ended in Dec. 2024 was HK$0.00 Mil.

Sunho Biologics's quarterly Accounts Payable increased from Dec. 2023 (HK$0.00 Mil) to Jun. 2024 (HK$10.30 Mil) but then declined from Jun. 2024 (HK$10.30 Mil) to Dec. 2024 (HK$0.00 Mil).


Sunho Biologics Accounts Payable Historical Data

The historical data trend for Sunho Biologics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics Accounts Payable Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23 Dec24
Accounts Payable
- - -

Sunho Biologics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24
Accounts Payable - - - 10.30 -

Sunho Biologics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Sunho Biologics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunho Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
Executives
Sunho Fortune Investments Limited 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Zhang Feng 2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited 2101 Beneficial owner

Sunho Biologics Headlines

No Headlines